Skip to main content


Head and Neck Cancer

Featured

Guideline Updates
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
Guideline Updates
NCCN released an update to its clinical practice guideline for esophageal and esophageal junction cancers, adding fam-…
Quiz
True or False: In combination with radiotherapy, cisplatin is inferior to cetuximab for the locoregional control of…
News
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and…
News
The FDA granted approval to pralsetinib for patients with advanced or metastatic RET-mutant medullary thyroid cancer or…
Back to Top